As obesity rates soar globally, glucagon-like peptide-1 (GLP-1) receptor agonists are gaining traction for their significant weight-loss potential, with some users shedding up to 20% of their body weight. The market for these medications is projected to exceed USD 160 billion by 2031, driven by their effectiveness in treating various metabolic and systemic conditions, including type 2 diabetes and sleep apnea. However, challenges such as side effects, high costs, and limited availability may hinder long-term patient compliance, despite the growing demand for innovative obesity treatments.